Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the William Blair 45th Annual Growth Stock Conference. CEO and Co-founder Jane Chao, Ph.D., will deliver a presentation on Tuesday, June 3, 2025, at 7:20 a.m. PST / 9:20 a.m. CST. Investors can access both live and archived versions of the presentation through the company's investor relations website at https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), un'azienda di tecnologia medica specializzata nella diagnosi e gestione delle condizioni neurologiche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale William Blair sulle Azioni in Crescita. La CEO e cofondatrice Jane Chao, Ph.D., terrà una presentazione martedì 3 giugno 2025, alle 7:20 PST / 9:20 CST. Gli investitori potranno accedere sia alla versione in diretta sia agli archivi della presentazione tramite il sito web delle relazioni con gli investitori della società all'indirizzo https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), una empresa de tecnología médica especializada en el diagnóstico y manejo de condiciones neurológicas, ha anunciado su participación en la 45ª Conferencia Anual de Acciones de Crecimiento de William Blair. La CEO y cofundadora Jane Chao, Ph.D., realizará una presentación el martes 3 de junio de 2025, a las 7:20 a.m. PST / 9:20 a.m. CST. Los inversores pueden acceder tanto a la versión en vivo como a las grabaciones de la presentación a través del sitio web de relaciones con inversionistas de la compañía en https://investors.ceribell.com/.
Ceribell(NASDAQ: CBLL)은 신경학적 질환 진단 및 관리에 특화된 의료 기술 회사로, William Blair 제45회 연례 성장주 컨퍼런스에 참여한다고 발표했습니다. CEO이자 공동창립자인 Jane Chao 박사가 2025년 6월 3일 화요일 오전 7:20 PST / 오전 9:20 CST에 발표를 진행할 예정입니다. 투자자들은 회사 투자자 관계 웹사이트 https://investors.ceribell.com/를 통해 실시간 및 녹화된 발표를 모두 시청할 수 있습니다.
Ceribell (NASDAQ : CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic et la gestion des troubles neurologiques, a annoncé sa participation à la 45e conférence annuelle William Blair sur les actions de croissance. La PDG et cofondatrice Jane Chao, Ph.D., fera une présentation le mardi 3 juin 2025 à 7h20 PST / 9h20 CST. Les investisseurs peuvent accéder aux versions en direct et archivées de la présentation via le site web des relations investisseurs de la société à l'adresse https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), ein Medizintechnikunternehmen, das sich auf die Diagnose und Behandlung neurologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen William Blair Growth Stock Conference angekündigt. CEO und Mitgründerin Jane Chao, Ph.D., wird am Dienstag, den 3. Juni 2025, um 7:20 Uhr PST / 9:20 Uhr CST eine Präsentation halten. Investoren können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die Investor-Relations-Website des Unternehmens unter https://investors.ceribell.com/ abrufen.
Positive
None.
Negative
None.
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
